A study found that chronic thromboembolic pulmonary hypertensio (CTEPH) patients had significantly more of an antioxidant enzyme (peroxiredoxin 2, or PRDX2) in their bloodstream compared to healthy patients. Using rats, the researchers determined that PRDX2 helped reduce inflammation, suggesting that it has a protective role and might have therapeutic use. Read the Scientific Reports article

This study examined the causes of delayed diagnosis (diagnosis after approximately 22 months) of pulmonary arterial hypertension (PAH) and whether an earlier diagnosis (within six months) leads to better outcomes. They identified several factors associated with delayed diagnosis and found that earlier diagnosis and treatment were associated with better survival. Read the Pulmonary Circulation article

A relatively simple, inexpensive, and minimally invasive test for idiopathic pulmonary arterial hypertension (IPAH) would aid in the diagnosis of this disease. This study found that levels of the NOTCH3 extracellular domain (NOTCH3-ECD) shed into blood serum could be used as a biomarker for IPAH. They found that NOTCH3-ECD levels did correlate with the presence and severity of IPAH. Read the Nature Medicine article